{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:39:06Z","timestamp":1787647146478,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.4158\/ep08178.orr","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T21:42:24Z","timestamp":1249422144000},"page":"705-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Alendronate Therapy in Men With Primary Hyperparathyroidism"],"prefix":"10.1016","volume":"15","author":[{"given":"Aliya A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy I.","family":"Standish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba A.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP08178.ORR_bb0005","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"187","article-title":"the American Society for Bone and Mineral Research","author":"Bilezikian","year":"1999"},{"issue":"suppl 2","key":"10.4158\/EP08178.ORR_bb0010","first-page":"N18","article-title":"Epidemiology of primary hyperparathyroidism in Europe","volume":"17","author":"Adami","year":"2002","journal-title":"J Bone Miner Res."},{"issue":"suppl 2","key":"10.4158\/EP08178.ORR_bb0015","first-page":"N12","article-title":"The epidemiology of primary hyperparathyroidism in North America","volume":"17","author":"Melton","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08178.ORR_bb0020","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"302","article-title":"Primary hyperparathyroidism","author":"Silverberg","year":"2008"},{"key":"10.4158\/EP08178.ORR_bb0025","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0030","first-page":"335","article-title":"Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism","volume":"94","author":"Bilezikian","year":"2009","journal-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0035","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2362.2007.01874.x","article-title":"The role of calcimimetics in the treatment of hyperparathyroidism","volume":"37","author":"W\u00fcthrich","year":"2007","journal-title":"Eur J Clin Invest."},{"key":"10.4158\/EP08178.ORR_bb0050","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00019616-200111000-00006","article-title":"Alendronate therapy of primary hyperparathyroidism","volume":"11","author":"Hassani","year":"2001","journal-title":"Endocrinologist."},{"key":"10.4158\/EP08178.ORR_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP08178.ORR_bb0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4158\/EP09162.CO","article-title":"Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract."},{"key":"10.4158\/EP08178.ORR_bb0075","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid- related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0085","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP08178.ORR_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/jc.2008-1762","article-title":"Medical management of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop","volume":"94","author":"Khan","year":"2009","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20415526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/073351261M1671Q1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:49:20Z","timestamp":1761515360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20415526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1530891X20415526"],"URL":"https:\/\/doi.org\/10.4158\/ep08178.orr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alendronate Therapy in Men With Primary Hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP08178.ORR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}